Prof. Hamdi Levent Doganay Artikuj
1. Tanriover MD., Doğanay L, Akova M., Güner HR, Azap A, Akhan S., Köse Ş, Erdinç FŞ, Akalın EH., Tabak EF, Pullukçu H., Batum Ö., Yavuz S., Turhan Ö. ., Yıldırmak MT., Köksal İ., Taşova Y., Korten V., Yılmaz G., Çelen MK., Altın S., Çelik İ., Bayındır Y., Karaoğlan İ., Yılmaz A., Özkul A., Gür H., Unal S., and the CoronaVac Study Group. Efficacy and safety of an inactivated whole virion SARS-CoV-2 vaccine, CoronaVac: interim results of a randomized, double-blind, placebo-controlled phase III clinical trial in Turkey, Lancet 2021;398(10296):213-22. doi: 10.1016/S0140-6736(21)01429-X.
2. Tanriover MD., Doğanay L, Serhat Ünal, Akova M. Coronavac efficacy data from Turkey. Lancet 2021; 398(10314):1874. Doi: 0.1016/S0140-6736(21)02286-8.
3. Ozfiliz Kilbas P., Can ND, Kizilboga T., Ezberci F., Doganay L., Arisan DE, Dinler Doganay G. CRISPR/Cas9-Mediated Bag-1 knockout increased mesenchymal characteristics of MCF-7 cells via Akt hyperactivation- mediated actin cytoskeleton remodeling. Plos One. accepted, on publication.
4. Zhong W, Altay O, Arif M, Edfors F, Doganay L, Mardinoglu A, Uhlen M, Fagerberg L. Next generation plasma proteome profiling of COVID-19 patients with mild to moderate symptoms. EBioMedicine. 2021 doi: 10.1016/j.ebiom.2021.103723. Epub ahead of print. PMID: 34844191; PMCID: PMC8626206.
5. Akgun-Dogan O, Ağaoğlu NB, Demirkol YK, Doğanay L, Ergül Y, Karacan M. Mutational Spectrum of Congenital Long QT Syndrome in Turkey; Identification of Twelve Novel Mutations Across KCNQ1, KCNH2, SCN5A, KCNJ2, CACNA1C, CALM1. J Cardiovasc Electrophysiol. 2021 Dec 3. doi: 10.1111/jce.15306. Epub ahead of print. PMID: 34860437.
6. Altay O., Yang H., Aydin M., Alkurt G., Altunal N., Kim W., Akyol D., Arif M., Zhang C., Dinler-Doganay G., Turkez H. ., Shoaie S., Nielsen J., Boren J., Doganay L., Uhlen M., Mardinoglu A. Combined metabolic coactivators accelerates recovery in mild to-moderate COVID-19, Advanced Science. doi.org/10.1002/advs.202101222.
7. Agaoglu NB, Doganay L. Concurrent pathogenic variations in patients with hereditary cancer syndromes, European Journal of Medical Genetics, 2021;64(12);104366. doi: 10.1016/j.ejmg.2021.104366.
8. Can ND, Basturk E., Kizilboga T., Akcay IM, Dingiloglu B., Acar S., Elibeyli E., Muratcıoglu S., Januzzi A., Gursoy A., Keskin O., Doğanay HL, Karademir-Yilmaz B., Dinler-Doganay G. Interactome analysis of Bag-1 isoforms reveals novel interaction partners in ER- associated degradation. Plos One 2021;16(8):e0256640. doi: 10.1371/journal.pone.0256640.
9. Gokcen P., Guzelbulut F., Adalı G., Degirmenci AG, Ozturk O., Bahadır O., Kanatsiz E., Kiyak M., Ozdil K., Doganay L. Validation of the PAGE-B Score to Predict Hepatocellular Carcinoma Risk in Caucasian Chronic Hepatitis B Patients on Treatment World Journal of Gastroenterology, accepted, on publication.
10. Alm E, Broberg EK, Connor T, Hodcroft EB, Komissarov AB, Maurer-Stroh S, Melidou A, Neher RA, O'Toole Á, Pereyaslov D; WHO European Region sequencing laboratories and GISAID EpiCoV group; WHO European Region sequencing laboratories and GISAID EpiCoV group*. Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020. Euro Surveill. 2020 Aug;25(32):2001410. doi: 10.2807/1560-7917.ES.2020.25.32.2001410.
11. Karacan I., Akgun TK, Agaoglu NB, Zolfagharian P., Aydin M., Alkurt G., Yildiz J., Kose B., Can ND, Ozel AS, Altunal N., Irvem A., Demirkol Y., Akgun-Dogan O., Doganay L, Dinler-Doganay G. Genomic Diversity of the SARS-CoV-2 in Turkey and the Impact of Virus Genome Mutations on Clinical Outcomes. (Under review)
12. Doganay L, Agaoglu NB, Irvem A, Alkurt G, Yildiz J, Kose B, Demirkol YK, Dogan OA, Doganay GD. Responding to COVID-19 in Istanbul: Perspective from genomic laboratory. North Clin Istanbul 2020;7(3):311-312. doi: 10.14744/nci.2020.30075.
13. Karacan I, Akgun TK, Agaoglu NB, Irvem A, Alkurt G, Yildiz J, Kose B, Ozel AS, Altunal LN, Can ND, Demirkol YK, Aydin M, Dogan OA, Doganay L, Doganay GD. The origin of SARS-CoV-2 in Istanbul: Sequencing findings from the epicenter of the pandemic in Turkey. North Clin Istanbul 2020;7(3):203-209. doi: 10.14744/nci.2020.90532.
14. Alkurt G., Ahmet M., Aydın Z., Tatlı O., Agaoglu NB., Irvem A., Aydın M., Karaali R., Günes, M., Yeşilyurt B., Türkez H., Mardinoglu A. , Doganay M., Basinoglu F., Seyahi N., Dinler Doganay G., Doganay L. Seroprevalence of Coronavirus Disease 2019 (COVID-19) Among Health Care Workers from Three Pandemic Hospitals of Turkey, Plos One 2021:16(3) : e0247865, doi: 10.1371/journal.pone.0247865.
15. Dogan OA, Kose B., Agaoglu NB, Yildiz J., Alkurt G., Demirkol YK, Irvem A., Dinler-Doganay G., L Doganay. Does sampling saliva increase detection of SARS-CoV-2 by RT-PCR? Comparing saliva with oro-nasopharyngeal swabs. J Virologic Methods 2021(290): 114049. doi: 10.1016/j.jviromet.2020.114049.
16. Agaoglu NB, Yıldız J., Dogan OA, Alkurt G., Kose B., Demirkol Y., Irvem A., Doganay L., Dinler-Doganay G. COVID-19 PCR Test Performance For Samples Stored At Ambient Temperature, J Virologic Methods accepted on publication.
17. Temiz MZ, Dincer MM, Hacibey I, Author RO, Celik C, Kucuk SH, Alkurt G, Doganay L, Yuruk E, Muslumanoglu AY. Investigation of SARS-CoV-2 in semen samples and the effects of COVID-19 on male sexual health by using semen analysis and serum male hormone profile: A cross-sectional, pilot study. Andrologia. 2020(26): e13912. doi: 10.1111/and.13912.
18. Akcay IM, Celik E, Agaoglu NB, Alkurt G, Kizilboga Akgun T, Yildiz J, Enc F, Kir G, Canbek S, Kilic A, Zemheri E, Ezberci F, Ozcelik M, Dinler Doganay G, Doganay L. Germline pathogenic variant spectrum in 25 cancer susceptibility genes in Turkish breast and colorectal cancer patients and elderly controls. Int J Cancer. 2021; 148(2): 285295. doi: 10.1002/ijc.33199.
19. Sayar S., Gökçen P., Aykut H., Adalı G., Doğanay HL, Özdil K. Can simple Non-Invasive Fibrosis Models Determine Prognostic Indicators (Fibrosis and Treatment Response) of Primary Biliary Cholangitis? Med Bull Sisli Etfal Hosp 2021;55(3):412–418. doi: 10.14744/SEMB.2021.95825.
20. Sayar S, Ayranci G, Kürbüz K, Ak Ç, Tarikçi Kiliç E, Kahraman R, Atalay R, Öztürk O, Çalişkan Z, Adali G, Doganay L, Özdil K. High frequency of gastric cancer precursor lesions in patients with gastric xanthelasma: a prospective case-control study. Eur J Gastroenterol Hepatol. 2020;32(9):1130-1134. doi:10.1097/MEG.0000000000001795.
21. Sözeri B, Demir F, Sönmez HE, Karadağ ŞG, Demirkol YK, Doğan ÖA, Doğanay HL, Ayaz NA. Comparison of the clinical diagnostic criteria and the results of the next generation sequence gene panel in patients with monogenic systemic autoinflammatory diseases. Clin Rheumatol. 2021;40(6):2327-37. doi: 10.1007/s10067-020-05492-8.
22. Demir F, Bolac GL, Merter T, Canbek S, Dogan OA, Demirkol YK, Yildiz J, Doganay HL, Sozeri B. The musculoskeletal system manifestations in children with familial Mediterranean fever. North Clin Istanbul 2020 4;7(5):438-442. doi: 10.14744/nci.2020.96636.
23. Sayar S, Kürbüz K, Kahraman R, Öztürk O, Çalışkan Z, Doğanay HL, Özdil K. Risk of hepatitis B reactivation during anti-TNF therapy; evaluation of patients with past hepatitis B infection. Turk J Gastroenterol. 2020;31(7):522-528. doi: 10.5152/tjg.2020.19295.
24. Demir F, Doğan ÖA, Demirkol YK, Tekkuş KE, Canbek S, Karadağ ŞG, Sönmez HE, Ayaz NA, Doğanay HL, Sözeri B. Genetic panel screening in patients with clinically unclassified systemic autoinflammatory diseases. Clin Rheumatol. 2020;39(12):3733-3745. doi: 10.1007/s10067-020-05108-1.
25. Sayar S, Kurbuz K, Kahraman R, Caliskan Z, Atalay R, Ozturk O, Doganay HL, Ozdil K. A practical marker to determine acute severe ulcerative colitis: CRP/albumin ratio. North Clin Istanbul 2019:25;7(1):49-55. doi: 10.14744/nci.2018.78800.
26. Bulur A, Ozdil K, Doganay L, Ozturk O, Kahraman R, Demirdag H, Caliskan Z, Mutlu Bilgic N, Kanat E, Serap Erden A, Mehmet Sokmen H. Polypoid lesions detected in the upper gastrointestinal endoscopy: A retrospective analysis in 19560 patients, a single-center study of a 5-year experience in Turkey. North Clin Istanbul 2020 Nov 27;8(2):178-185. doi: 10.14744/nci.2020.16779.
27. Sozeri B, Ercan G, Dogan OA, Yıldız J, Demir F, Doğanay L. The same mutation in a family with adenosine deaminase 2 deficiency. Rheumatol Int. 2021;41(1). doi: 10.1007/s00296-019-04444-z.
28. Geyik G, Sahin A, Pekcioglu Y, Okuroglu N, Doganay L, Ozdil K. Is NRS-2002 a reliable tool in the nutritional assessment of cirrhosis: A comparative study. Acta Medica Mediterranea. 2021;37(1):43–50.
29. Güzelbulut F, Gökçen P, Can G, Adalı G, Değirmenci Saltürk AG, Bahadır Ö, Ozdil K., Doganay L. Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy Journal of Viral Hepatitis. 2021;28(5).
30. Gokcen P, Cakmak E, Adali G, Dogan HO, Yildiz SN, Ozturk O, Doganay L, Ozdil K. Liver Fatty Acid Binding Protein: Is it an early diagnostic and prognostic marker in liver damage? Medical Science and Discovery. 2021;8(4).
31. Sayar S, Atalay R, Çakmak Ş, Ayrancı G, Kürbüz K, Kahraman R, Caliskan Z., Ozturk O., Demirdağ H., Adali G., Ozdil K., Doganay L. Diagnostic Performance of Non-invasive Fibrosis Indexes in Hepatitis B Related Fibrosis. Viral Hepatitis Journal. 2020;26(2).
32. Değertekin B, Demir M, Akarca US, Kani HT, Üçbilek E, Yıldırım E, Güzelbulut F, Balkan A, Vatansever S, Danış N, Demircan M, Soylu A, Yaras S, Kartal A, Kefeli A, Gündüz F, Yalçın K, Erarslan E, Aladağ M, Harputluoğlu M, Özakyol A, Temel T, Akarsu M, Sümer H, Akın M, Albayrak B, Sen İ, Alkım H, Uyanıkoğlu A, Irak K, Öztaşkın S, Uğurlu ÇB, Güneş Ş , Gürel S, Nuriyev K, İnci İ, Kaçar S, Dinçer D, Doğanay L, Göktürk HS, Mert A, Coşar AM, Dursun H, Atalay R, Akbulut S, Balkan Y, Koklu H, Şimşek H, Özdoğan O, Çoban M. Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience. Turk J Gastroenterol. 2020 Dec;31(12):883-893. doi: 10.5152/tjg.2020.20696.
33. Çalışkan Z, Demircioglu K, Sayar S., Kahraman R., Caklili Ö, Özcan FB, Köstek Ö, Baycan OF, Doganay L, Caliskan M. Lipid profile, atherogenic indices, and their relationship with epicardial fat thickness and carotid intima –media thickness in celiac disease. North Clin Istanbul 2019; 6(3): 242-247. doi: 10.14744/nci.2019.54936.
34. Akcay IM, Katrinli S, Ozdil K, Doganay GD, Doganay L. Host genetic factors affecting hepatitis B infection outcomes: Insights from genome-wide association studies. World J Gastroenterol. 2018;24(30):3347-3360. doi: 10.3748/wjg.v24.i30.3347.
35. Celik E, Ermis Tekkus K, Akcay IM, Alkurt Sal G, Ezberci F, Dinler Doganay G, Doganay L. Identification of a BRCA2 mutation in a Turkish family with early-onset breast cancer. Clin Case Rep. 2018;6(9):1751-1755. doi: 10.1002/ccr3.1625.
36. Doganay L. Hepatocellular Cancer: Is Recurrence Inevitable? J Gastrointest Cancer. 2017. doi: 10.1007/s12029-017-9967-0.
37. Kilic E, Doganay L, Ozdil K. Endoscopic retrograde cholangiopancreaticography in elderly patients: A reliable alternative in sepsis. North Clin Istanbul 2018; 5(2): 169-170. doi: 10.14744/nci.2018.92679.
38. Katrinli S, Nigdelioglu A, Ozdil K, Dinler-Doganay G, Doganay L. The association of variations in TLR genes and spontaneous immune control of hepatitis B virus. Clin Res Hepatol Gastroenterol. 2018;42(2):139-144. doi: 10.1016/j.clinre.2017.10.002.
39. Ozdil K, Caliskan Z, Keles N, Ozturk O, Tekin AS, Kahraman R, Doganay L, Demircioglu K, Yilmaz Y, Caliskan M. Echocardiographic epicardial fat thickness measurement: A new screening test for subclinical atherosclerosis in patients with inflammatory bowel disease diseases North Clin Istanbul 2017;4(1):4-12. doi: 10.14744/nci.2017.74508.
40. Katrinli S, Gurbet-Erkut N, Ozdil K, Yilmaz-Enc F, Ozturk O, Kahraman R, Tuncer I, Dinler-Doganay G, Doganay L. HLA DPB1 15:01 Allele Predicts Spontaneus Hepatitis B Surface Antigen Seroconversion. Acta Gastro-enterologica Belgica. 2017;80(3):351.
41. Katrinli S, Ozdil K, Sahin A, Kir G, Baykal AT, Akgun E, Sarac OS, Sokmen M, DinlerDoganay G, Doganay L. Proteomic profiling of HBV infected liver biopsies with different fibrotic stages. Proteome Science 2017;15:7. doi: 10.1186/s12953-017-0114-4.
42. Ozturk O, Doganay L, Colak Y, Yilmaz Enc F, Ulasoglu C, Ozdil K, Tuncer I. Therapeutic Success with Bismuth-containing Sequential and Quadruple Regimens in Helicobacter pylori Eradication. Arab Journal of Gastroenterology, 2017. doi: 10.1016/j.ajg.2017.05.002.
43. Doganay L, Ozdil K, Memisoglu K, Katrinli S, Karakoc E, Nikerel E, Doganay G. Integrating Personalized Genomics To Turkish Health Care System: A Cancer Oriented Pilot Activity of Istanbul Northern Anatolian Public Hospitals with GLAB. North Clin Istanbul 2017; 4(1):1-3. doi: 10.14744/nci.2017.38980.
44. Katrinli S, Yilmaz Enc F, Ozdil K, Ozturk O, Tuncer I, Dinler Doganay G, Doganay L. Effect of HLA-DPA1 Alleles on Chronic Hepatitis B Prognosis and Treatment Response. North Clin Istanb 2016;3(3):168-174. doi: 10.14744/nci.2016.27870.
45. Ozdil K., O. Ozturk, ES Calik, ES Akbas, E. Kanat, Z. Caliskan, H. Demirdag, R. Kahraman, A. Bulur, NM Bilgic, Doganay L., HM Sokmen. Relationship between size of varices and platelet count/spleen size ratio in cirrhotic patients. North Clin Istanbul 2016;3(1):46-52. doi: 10.14744/nci.2016.60362.
46. Ozturk O, Colak Y, Senates E, Yilmaz Y, Ulasoglu C, Doganay L, Ozkanli S, Oltulu YM, Coskunpinar E, Tuncer I. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease. World J Gastroenterol. 2015;21(26):8096-102. doi:10.3748/wjg.v21.i26.8096.
47. Gonen C, Gunduz F, Doganay L, Enc FY, Yegin EG, Ahishali E, Erdem E, Sokmen M, Tuncer I, Ozdogan O. High treatment modification rates with lamivudine therapy in HBV-infected patients with low baseline viremia and early virological response: A multicenter study. J Dig Dis. 2015 May;16(5):286-92. doi: 10.1111/1751-2980.12237.
48. Doganay L, Katrinli S, Colak Y, Senates E, Zemheri E, Ozturk O, Enc FY, Tuncer I, Doganay GD. HLA DQB1 alleles are related with nonalcoholic fatty liver disease. Mol Biol Rep. 2014;41(12):7937-43. doi: 10.1007/s11033-014-3688-2.
49. L. Doganay, A. Fejzullahu, S. Katrinli, F. Yilmaz Enc, O. Ozturk, Y. Colak, C. Ulasoglu, I. Tuncer, G. Dinler Doganay. Association of human leukocyte antigen DQB1 and DRB1 alleles with chronic hepatitis B. World J Gastroenterol. 2014 Jul 7;20(25):8179-86. doi: 10.3748/wjg.v20.i25.8179.
50. L. Doganay, I. Tuncer, S. Katrinli, FY Enc, O. Ozturk, Y. Colak, C. Ulasoglu, G. Dinler. The effect of HLA-DQB1 alleles on virologic breakthroughs during chronic hepatitis B treatment with genetically low barrier drugs. Clinics and research in hepatology and gastroenterology. 2013 Sep;37(4):359-64. doi: 10.1016/j.clinre.2012.10.013.
51. T. Calhan, R. Kahraman, A. Sahin, E. Senates, HL Doganay, E. Kanat, K. Ozdil, HM Sokmen. Efficacy of Two Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori: A Pilot Study. Helicobacter 2013 Oct;18(5): 378-83. doi: 10.1111/hel.12056.
52. Y. Yilmaz, O. Ozturk, YO Alahdab, E. Senates, Y. Colak, HL Doganay, E. Coskunpinar, YM Oltulu, F. Eren, O. Atug, I. Tuncer, N. Imeryuz. Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease. Digestive and liver disease. 2013 Jan;45(1):58-62. doi: 10.1016/j.dld.2012.08.017.
53. L. Doganay, K. Ozdil, M. Sokmen. Last blood check before passing: does alcohol prevent fibrosis? The American journal of gastroenterology. 2013 Jun;108(6):1010. doi: 10.1038/ajg.2013.74.
54. Y. Colak, E. Senates, A. Yesil, Y. Yilmaz, O. Ozturk, L. Doganay, E. Coskunpinar, OT Kahraman, B. Mesci, C. Ulasoglu, I. Tuncer. Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine. 2013 Feb;43(1):100-7. doi: 10.1007/s12020-012-9712-1.
55. C. Ulasoglu, B. Isbilen, L. Doganay, F. Ozen, S. Kiziltas, I. Tuncer. Effect of Helicobacter pylori eradication on serum ghrelin and obestatin levels. World journal of gastroenterology. 2013 Apr 21;19(15):2388-94. doi: 10.3748/wjg.v19.i15.2388.
56. Y. Colak, I. Tuncer, E. Senates, O. Ozturk, L. Doganay, Y. Yilmaz. Nonalcoholic fatty liver disease: a nutritional approach. Metabolic syndrome and related disorders. 2012 Jun;10(3):161-6. doi: 10.1089/met.2011.0145.
57. Y. Colak, E. Senates, E. Coskunpinar, YM Oltulu, E. Zemheri, O. Ozturk, L. Doganay, B. Mesci, Y. Yilmaz, FY Enc, S. Kiziltas, C. Ulasoglu, I. Tuncer. Concentrations of connective tissue growth factor in patients with nonalcoholic fatty liver disease: association with liver fibrosis. Disease markers. 2012;33(2):77-83. doi: 10.3233/DMA2012-0907.
58. Tuncer, Y. Colak, R. Yigitbasi, E. Zemheri, T. Ayaz, E. Yorulmaz, L. Doganay, O. Ozturk, G. Adali. Mesenteric inflammatory veno-occlusive disease: an unusual cause of colonic ischemia. The Turkish journal of gastroenterology. 2011 Oct;22(5):561-2. doi: 10.4318/tjg.2011.0262.
59. Y. Colak, CY Karabay, I. Tuncer, G. Kocabay, A. Kalayci, E. Senates, O. Ozturk, HL Doganay, FY Enc, C. Ulasoglu, S. Kiziltas. Relation of epicardial adipose tissue and carotid intima-media thickness in patients with nonalcoholic fatty liver disease. European journal of gastroenterology & hepatology. 2012 Jun;24(6):613-8. Doi: 10.1097/MEG.0b013e3283513f19.
60. L. Doganay, S. Kiziltas, Y. Colak, M. Gulluoglu, I. Tuncer. Is the lymphoma risk reduced in viral hepatitis? A cirrhotic patient with triple malignancies. The American journal of gastroenterology. 2011 Sep;106(9):1719-20; author reply 20. doi: 10.1038/ajg.2011.214.
61. Y. Colak, O. Ozturk, E. Senates, I. Tuncer, E. Yorulmaz, G. Adali, L. Doganay, FY Enc. SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Medical science monitor. 2011 May;17(5):HY5-9. doi: 10.12659/msm.881749.
62. Tuncer, L. Doganay, O. Ozturk. Instant control of fundal variceal bleeding with a folkloric medicinal plant extract: Ankaferd Blood Stopper. Gastrointestinal Endoscopy. 2010 Apr;71(4):873-5. doi: 10.1016/j.gie.2009.08.021.
63. Y. Colak, E. Senates, O. Ozturk, HL Doganay, E. Coskunpinar, YM Oltulu, A. Eren, O. Sahin, S. Ozkanli, FY Enc, C. Ulasoglu, I. Tuncer. Association of serum lipoprotein associated phospholipase A2 level with nonalcoholic fatty liver disease. Metabolic syndrome and related disorders. 2012 Apr;10(2):103-9. doi: 10.1089/met.2011.0111.
64. HA Bodur, E. Saygili, S. Saygili, LH Doganay, S. Yesil. Continuous infusion of subcutaneous compared to intravenous insulin for tight glycaemic control in medical intensive care unit patients. Anaesthesia and intensive care. 2008 Jul;36(4):520-7. doi: 10.1177/0310057X0803600421.
65. L. Doganay, PD Welsby. Anthrax: a disease in waiting? Postgraduate medical journal. 2006 Nov;82(973):754-6. doi: 10.1136/pgmj.2005.044487.
66. L. Doganay, B. Akinci, N. Pekel, I. Simsek, H. Akpinar. Mesalazine-induced myopericarditis in a patient with ulcerative colitis. International journal of colorectal disease. 2006 Mar;21(2):199-200. doi: 10.1007/s00384-004-0706-1.
